Recent Advancements in the Chitosan‐Decorated Nasal Drug Delivery Systems: Biopharmaceutical Characteristics, Patent Reports, and Clinical Trials
Starch - Stärke · 2026-07 · 78 (7)
DOI: 10.1002/star.70256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Starch - Stärke, online erschienen am 07.07.2026. Verfasst von Abdul Hafeez. Die Arbeit nennt 130 Literaturangaben.
Abstract (Originalsprache)
Different routes of drug delivery are being investigated for improvement in the therapeutic effectiveness of drugs in the context of improvement in drug bioavailability, reduction in adverse effects, and drug targeting. The nasal route of drug delivery has shown potential for the treatment of local, systemic, and brain diseases. This route has the advantages of easy administration, fast drug absorption (comparable to parenteral administration), and direct drug targeting to the brain via the trigeminal and olfactory nerves. The problems associated with this route are rapid mucociliary clearance of most of the drug formulations and low permeation of hydrophilic and high molecular weight drugs. Several absorption enhancers with mucoadhesive properties have been tested for nasal drug delivery applications. Chitosan (CH), a polysaccharide, has shown high potential as a penetration enhancer with mucoadhesion characteristics in different nasal drug formulations. The Scopus, Springer, Elsevier, PubMed, Bentham Science, Taylor & Francis, ClinicalTrials.gov, Google Patents, and PatentScope electronic databases were searched for publications published between 2020 and 2025. The present review discusses the important aspects of nasal drug delivery, properties of CH, and recent biopharmaceutical advancements in the CH‐based nasal drug delivery systems (polymeric nanoparticles, niosomes, micro/nanospheres, nanoemulsions, solid lipid nanoparticles, aerogel particles, liposomes, nanostructured lipid carriers, nanoethosomes, and nanotransfersomes) utilized for the management of different diseases. Clinical trials and patent reports further strengthen the clinical translational potential of CH‐based nasal drug delivery systems.
Zitieren
APA
Hafeez, A. (2026). Recent Advancements in the Chitosan‐Decorated Nasal Drug Delivery Systems: Biopharmaceutical Characteristics, Patent Reports, and Clinical Trials. Starch - Stärke, 78(7). https://doi.org/10.1002/star.70256
Vancouver
Hafeez A. Recent Advancements in the Chitosan‐Decorated Nasal Drug Delivery Systems: Biopharmaceutical Characteristics, Patent Reports, and Clinical Trials. Starch - Stärke. 2026;78(7). doi:10.1002/star.70256
BibTeX
@article{Hafeez2026,
author = {Hafeez, Abdul},
title = {Recent Advancements in the Chitosan‐Decorated Nasal Drug Delivery Systems: Biopharmaceutical Characteristics, Patent Reports, and Clinical Trials},
journal = {Starch - Stärke},
year = {2026},
volume = {78},
number = {7},
doi = {10.1002/star.70256}
}
EUVIMED